Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

Neuroblastoma (NB) is a pediatric tumor that originates from neural crest-derived cells
undergoing a defective differentiation due to genomic and epigenetic impairments …

Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-
clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …

Chimeric antigen receptor‐T (CAR‐T) cell immunotherapy has shown impressive clinical
outcomes for hematologic malignancies. However, its broader applications are challenged …

Neuroblastoma is a tumor of the peripheral sympathetic nervous system, derived from
multipotent neural crest cells (NCCs). To define core regulatory circuitries (CRCs) controlling …

Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic
agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) …

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from
cure in> 90% of patients with low risk disease to< 50% for those with high risk disease …

There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is
the most common pediatric solid tumor, and accounts for~ 15% of childhood cancer‐related …

The majority of patients with neuroblastoma have tumors that initially respond to
chemotherapy, but a large proportion will experience therapy-resistant relapses. The …

The MYC oncoproteins are thought to stimulate tumor cell growth and proliferation through
amplification of gene transcription, a mechanism that has thwarted most efforts to inhibit …